Valiant Laboratories Limited has informed the Exchange regarding Resignation of Prajakta Patil as Company Secretary & Compliance Officer of the company w.e.f. Jun 15, 2025.
VALIANTLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Valiant Laboratories' board met on May 20, 2025 and approved audited standalone and consolidated results for Q4 and FY ending March 31, 2025. On a standalone basis, Q4 FY25 revenue from operations rose sharply to Rs. 5,777 lakhs (vs Rs. 3,058 lakhs in Q4 FY24), and Q4 net profit jumped to Rs. 323.83 lakhs (vs Rs. 121.76 lakhs). However, full-year FY25 standalone revenue fell to Rs. 13,336 lakhs (from Rs. 18,205 lakhs) and the company swung to a standalone net loss of Rs. 144.78 lakhs, compared to a Rs. 34.03 lakh profit in FY24. On a consolidated basis, FY25 net loss was Rs. 220.12 lakhs, dragged by subsidiary Valiant Advanced Sciences (total assets of Rs. 40,085.75 lakhs). The board also re-appointed the Cost Auditor (Ketki D Visariya & Co.) and Internal Auditor (Rajesh Chheda & Co.) for FY 2025-26, and accepted the resignation of Company Secretary & Compliance Officer Ms. Prajakta Patil effective June 15, 2025, citing an alternate career opportunity. The Audit Committee and Risk Management Committee were reconstituted accordingly.
Mixed signals for shareholders: while Q4 FY25 showed a strong recovery in profits, the full-year swung to a loss on both standalone and consolidated bases, reflecting weak annual performance. The Company Secretary's exit is a routine KMP change and should not materially affect operations, though investors will watch for a timely replacement.